Loading the company…
Loading the company…
㈜롯데바이오로직스
English name as filed with DART, Korea’s corporate disclosure system · Correct the English name ›
Last updated 2026-11-02 · Korean page ›
Verification level — how far we have checked
L0 · Public records — NPS workforce · filed financials · patents — public data
A company based in Seoul, founded in 2022. Industry: Bio & Pharma. Group consolidated revenue for 2025 was ₩196.1bn — this includes subsidiaries and is not the revenue of this entity alone. It has 754 employees enrolled in the National Pension Service (as of Aug 2026). It is externally audited; the latest audit opinion is “Unqualified”.
Loading…
Latest filing 2026-01-23 · newest first
본 발명의 링커-약물 접합체는 표적화 물질(예를 들어, 항체)에 대한 부착기 - 분지 스페이서 - 약물의 연결 구조에서 분지 스페이서에 분지 사슬로서 펩타이드가 연결된 구조를 기본 구조로서 가지며, 본 발명의 표적화 물질-약물 접합체는 이러한 링커-약물 접합체 구조에서 부착기에 표적화 물질이 연결된 구조를 갖는다.
KIPO KIPRIS · checked 2026-10-15 · newest filings first · right: registration date (filing date if not yet registered) · 1 of 1 · titles and abstracts are in Korean as filed · click a row for details ▾
For now we hold public records only (National Pension Service · DART filings · patents · registers · press). When the company files material in our IR Room, it moves to L1. We do not score or rate companies — we only state how far we have checked.
| KRW bn | 2024 | 2025 |
|---|---|---|
| Revenue | 234.4 | 196.1 |
| Cost of sales | 257.6 | 261.4 |
| Gross profit (loss) | (23.2) | (65.3) |
| Selling, general and administrative expenses | 56.9 | 67.4 |
| Operating income (loss) | (80.1) | (132.6) |
| Non-operating income | 11.7 | 11.0 |
| Other gains | 5.9 | 4.9 |
| Finance income | 5.8 | 6.0 |
| Non-operating expenses | 14.4 | 17.3 |
| Other losses | 5.4 | 5.3 |
| Finance costs | 9.0 | 12.0 |
| Profit (loss) before tax | (82.8) | (139.0) |
| Income tax expense | 7.0 | 2.4 |
| Net income (loss) | (89.7) | (141.4) |
Revenue ₩196.1bn, down 16.3% YoY.
Operating margin -67.6% (prior -34.2%).
Net income ₩-141.4bn.
Need more than is shown here? Ask for more information — full review report · valuation · executive teaser · IM · competitor analysis · due diligence. Tell us what you need and we will reply by email with scope, cost and timing.
Is this your company?
If anything here is wrong, tell us — we check it against the original and correct it. You do not need to join. If you would like your financials verified and this page completed, that is a separate process.
Headlines and links to public articles only · not checked by us (original ↗) · articles are in Korean — English headlines are our translation; where none is shown, “Read in English ›” opens a machine translation · “Broker view” is a forecast, not reported results · checked 2026-11-05